Compare Gilead Sciences, Inc. (GILD) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Gilead Sciences, Inc. trades at $148.05 (market cap $182.40B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.64 (market cap $7.77B). The key difference: Gilead Sciences, Inc. is far larger — about 23.5× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| GILD | PDBC | |
|---|---|---|
Market Cap | $182.40B | $7.77B |
Volume | 4,469,821 | 6,100,303 |
Sector | Health | — |
52-Week High | $155.80 | $20.10 |
52-Week Low | $116.74 | $13.16 |
Typical Hold Time | 111 Days | 56 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.41 with a slight 0.26% decline. Technical indicators show a neutral overall signal with bullish moving averages. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodities amid geopolitical tensions. Recent institutional activity shows mixed signals with significant short interest growth alongside new institutional investments.
The outlook for PDBC remains tied to commodity market dynamics, with potential upside from continued geopolitical tensions and defensive portfolio shifts. However, risks include the 215% surge in short interest and commodity price volatility. The ETF offers exposure to broad commodities diversification but faces headwinds from potential market normalization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
